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Abstract Vaccine preventable dis-
eases are a major contributor to 
child morbidity and mortality espe-
cially in the Sub-Saharan Africa 
and Nigeria in particular. It ac-
counts for 17% of global total under
-five mortality per year and 22% of 
child mortality in Nigeria. This im-
plies that appropriate deployment of 
relevant vaccines would signifi-
cantly reduce mortality and speed 
up the achievement of Millennium 
Development Goal 4 (MDG 4). 
 
In this paper, the Paediatric Asso-
ciation of Nigeria recommends a 
comprehensive routine immuniza-
tion schedule for children of all 
ages striking a delicate balance be-
tween optimal immune response 
generation and avoidance of undue 
exposure to high risk environment; 




Vaccine preventable diseases are a major contributo to 
child morbidity and mortality especially in the Sub-
Saharan Africa and Nigeria in particular. It accounts for 
17% of global total under-five mortality per year.1 
In Nigeria, vaccine preventable diseases were responsi-
ble for 22% of child mortality amounting to over 
200,000 deaths per year.2 This implies that appropriate 

















 reduce mortality and speed up the achievement of Mil-
lennium Development Goal 4 (MDG 4). Although the 
Expanded Programme on Immunization (EPI) has been 
in place in Nigeria for more than 30 years (since 1979), 
the under five mortality has only decreased from 192 in 
1990 to 157 in 2008.3 Figure 1 shows the slow trend of 
progress in mortality rates in Nigeria across three suc-
cessive five year periods preceding the 2008 survey. 
Fig 1. Trends in early childhood mortality rates (Deaths per 1,000) 
Neonatal mortality: the probability of dying within the first month of life. Post-neonatal mortality: the difference between infant 
and neonatal mortality. Infant mortality: the probability of dying before the first birthday. Child mortality: the probability of 
dying between the first and fifth birthdays. Under-five mortality: the probability of dying between birth and the fifth birthday. 
Source: National Demographic and Health Survey 20083 
(      )
This is further corroborated by a study4 covering 1970-
2003 which showed that the EPI programme had little 
effect on under five mortality rate in Nigeria  
 
The World Health Organization (WHO) initiated the EPI 
in 1974 with the goal of making vaccines available to all 
children throughout the world. Since the commencement 
of the EPI in Nigeria in 1979, very limited number of 
‘new’ vaccines has been added to the initial basic rec-
ommended number. Over a period of about 30 years, 
only Hepatitis B and yellow fever vaccines have been 
added. Although there are plans to include Haemophilus 
influenza b (Hib) vaccine this year (2012) and later 
(2013), Pneumococcal vaccine; the pace of expansion i  
rather too slow in comparison to child morbidity and 
mortality rates. 
 
Hepatitis B vaccine was introduced into the country’s  
routine immunization schedule in 20045,6, 22 years after 
the vaccine became available in the global market in 
1982. Haemophilus influenza bvaccine which became 
available in 1987 is only being introduced in Nigera in 
2012 - 25 years later. Nigeria is the 45th out of 46 coun-
tries in the WHO African region to introduce the Hib 
vaccine (only before Guinea Bissau). Obviously, this 
trend does not augur well for the Nigerian child. 
Apart from the narrow range of antigens available to the 
average Nigerian child, routine immunization coverag  
has remained poor over the years. The Diphtheria-
Pertussis-Tetanus 3 (DPT 3) coverage has only in-
creased from 33 in 2004 to 69 in 2010.7 This persistent 
low coverage (Fig 2) together with frequent vaccine 
stock outs has greatly compromised the future of Nige-
rian children and requires urgent and focused attention 
from all concerned.  
Fig. 2:  DPT3 coverage for Nigeria. Source: WHO vaccine-preventable diseases: monitoring system 2011 global summary8  
aRegular data not available from 1997-2004. bRegular data not available from 1997-2003 
Additionally, the children who get to be immunized ac-
cording to our compromised schedule do not receive 
booster doses. This again increases their susceptibility to 
the same diseases in late childhood as acquired immu-
nity wanes. Booster antibody responses are not only
faster and stronger than the primary series, but are also 
more prolonged and of higher neutralizing capacity.9 
Most Nigerian children do not benefit from booster vac-
cine doses due to its total absence in the National routine 
immunization schedule. 
 
It is generally agreed that antibody titres are generally 
higher with increasing age of immunisation. As infants 
grow older, the immune system matures and transmitted 
maternal antibodies disappear. This explains the usual 
postponing of the commencement of primary series to at
least 6–8 weeks of age or even up to three months of age 
in some countries10 
 
Accelerated infant vaccine schedules in which three 
vaccine doses are given at a one month interval (2, 3, 4 
or 3, 4, 5 months) result in lower responses than sched-
ules in which more time elapses between doses (2, 4, 6 
months), or between the priming and boosting doses. 
However, vaccine antibodies elicited by primary immu-
nization with non-live vaccines eventually wane.9 Also, 
longer interval (> 4 months) between priming and boost-
ing doses allows time for affinity maturation of meory 
B cells leading to enhanced capacity to respond to an i-
gens and thus higher secondary responses.9,11  
 
Our primary doses are however, scheduled with shorter 
intervals. This is done for two major reasons; to ensure 
compliance and to induce early enough but moderate 
levels of protection before children are exposed to our 
high risk environment. There is therefore an even greater 
need for booster doses for Nigerian children so as to 
achieve optimum protective antibody levels and for 
longer duration. Studies have shown that the lower re-
sponse to early primary DPT vaccine series becomes 
insignificant after the booster dose.10 
 
According to WHO12, “several countries are appropri-
ately providing additional vaccine antigens, but they lag  
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behind in providing the adequate number of doses or 
booster doses for traditional vaccines and give littl  con-
sideration to older age groups.”There has not been ap-
preciable number of immunogenicity studies in respect 
of response to routine vaccines in our population so as to 
establish the adequacy of immune response and the 
length of protection. Data from disease surveillance and 
immunogenicity studies would enhance the periodic 
review of routine immunization schedule for the coun-
try. 
 
Vaccines should be administered to children at ages 
when optimal immune response would be obtained but 
also, before children are exposed to the risk of contract-
ing the target disease. Developing a routine immuniza-
tion schedule requires maintaining a delicate balance 
between these two factors and also ensuring that admin-
istered antigens are not neutralized by maternal antibod-
ies.  
 
In view of all the foregoing, it has become imperative to 
develop a more comprehensive National routine Immu-
nization Schedule for the country so as to significantly 
enhance the health of the Nigerian child. The general 
objective of this paper by the Paediatric Association of 
Nigeria (PAN) is to recommend an optimum National 
Routine Immunization Schedule that will help achieve 
an early comprehensive protection of the Nigerian child 
from major infectious causes of morbidity and mortality 
in the Nigerian environment. The specific objectives 
include; 
 
• To increase the number of antigens covered in the 
routine immunization schedule 
• To extend the schedule beyond infancy to include 
the older child and adolescents 
• To institutionalize and provide adequate number of 
booster doses 
• To maintain traditional antigens and improve on 
them 
• To advocate for the protection of the rights of our 
children to good health. 
• To provide guidelines for catch-up immunization 
for older children who are not previously immu-
nized. 
 
Opportunities and Strengths 
 
Currently, there is a level of Federal Government com-
mitment to immunization of children at the presidential, 
ministerial and agency levels (though more commitment 
needs to shift from polio only, to routine immunizat on). 
 
The basic health system structure that will drive routine 
immunization programme is already in place. These are 
structures from the Federal to State and Local Govern-
ments and even to wards and settlements. These have 
been well articulated in a micro plan by the National 
Primary Health Care Development Agency. It however 
requires revitalization and strengthening especially t 
the state and local government levels for effective func-
tioning. 
The National Health Bill has been carefully articulated 
and it is at an advanced stage of being signed into law. It 
has provisions for proper funding of health programmes 
and services. It is however regrettable that it took s  
long to get to the current stage, while children are dying. 
 
Data13,14 have shown that routine immunization is more 
acceptable to mothers in Nigeria and other countries 
than campaigns. The well known wave of OPV rejection 
in Northern Nigeria in 2003 was not to the routine OPV 




The challenges which are not insurmountable include 
wrong attitude and mal-orientation of health workers, 
poor political commitment, beaurocratic bottle-necks 
and low level of awareness. Others are poor global do-
nor interest in routine immunization and the overshad-
owing influence of supplemental immunization activi-
ties (SIAs) over routine immunization activities. Paedi-
atric Association of Nigeria is willing to partner with 
Governments to overcome these challenges. 
 
PAN Recommendations    
  
This is a follow up to the PAN position paper on immu-
nization which was submitted to Government in 2008. 
We here recommend an optimal routine immunization 
schedule that considers early exposure of Nigerian chil-
dren to infections, low response to too early and short 
interval primary series vaccination and therefore gr ater 
need for boosting. There should be enough resources to 
invest in the health of Nigerian children. The recom-
mended optimum schedule is presented in Tables 1 - 3 
below.                                                                                                             
                                                                                            
*The other type of typhoid vaccine, Ty21a, has liquid 
and capsule forms. The liquid form is no longer avail-
able. The capsule form for individuals > 5 years requires 
3-4 orally administered doses, taken every other day. If 
the schedule is interrupted by an interval > 21 days, re-
start the series from beginning. If the delay is less than 
21 days, resume series without repeating the previous 
dose. Booster doses are given after 3-7 years. 
**DTaP contains the normal infant doses of diphtheria 
tetanus and acellular pertussis vaccines. 
***Tdap contains lower doses of diphtheria and pertus-
sis, but same infant dose of tetanus; the size of the letter 
indicates the size of the dose. 
*+The other type of Cholera vaccine, Dukoral, is not 
licensed for children < 2 years. Children aged 2-5 years 
should receive 3 doses > 7 days apart (but not more than  
six weeks). Intake of food and drink should be avoided 
for one hour before and after vaccination. If the interval 
between doses is delayed for more than six weeks, pri-
mary vaccination should be restarted. One booster dose 
is recommended every six months, and if the interval 
between primary immunization, and the booster is more 
than 6 months, primary immunization must be restarted.  
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Adults and children less than six years should receiv  
two doses of Dukoral > 7 days apart (but not more than 
six weeks). Intake of food and drink should be avoided 
for one hour before and after vaccination. If the interval 
between doses is delayed for more than six weeks, pri-
mary vaccination should be restarted. A booster dose 
every two years is recommended. If the interval betwe n 
the primary series and booster immunization is more 
than two years, primary immunization must be repeated. 
 
+Tt immunization schedule for females of child bearing 
age (15 – 45 years) 
• TT 1 - First contact: No protection 
• TT 2 - 4 weeks after first dose: offers protection f r 
3 years 
• TT 3 - 6 months after 2nd dose: protects for 5 years 
Table 1: Proposed Routine Immunization Schedule from infancy to childhood and adolescents  
 
Age Vaccines Notes 
Birth 1BCG  0.05ml for infants < 12 months, 0.1ml for children > 
12 months 
  2OPV 0 If > 2 weeks, skip birth dose)  
  3Hep B-1(Birth dose) If > 2 weeks, skip birth dose) 
6 weeks OPV-1  
  4Penta-1 (Hib+DTP+Hep B)   
  5Rota 1  Do not give if child is >15 weeks (31/2 months) 
  6PCV13-1   
10 weeks OPV-2  
  Rota 2  Do not give if child is >32 weeks (8 months) 
14 weeks OPV-3  
  Penta-2   
  PCV13-2   
6 months Penta-3 Last dose of Hep B not given earlier than 24 weeks 
of age and 16 weeks from 1st dose 
 PCV 13-3 3rd dose given at a minimum of 2 months after 2nd 
dose 
 7Vit A-1 100,000 IU for 6-11 month old, 200,000 IU for > 12 
month old 
9 months Measles-1   
  Yellow fever Booster every 10 years 
12-15 months OPV   
  8DTaP- booster   
  Vit A-2 Repeat every 6 months until 5 years of age 
18 months Hepatitis A 2 doses at 6 months interval 
  10MMRV (or 11MMR + Var or Mea-
sles-2 + 9Var) 
  
2 years Typhoid (Vi Polysaccharide) vac-
cine* 
Re-vaccinate every 4 years 
5 years OPV   
  DTaP**   
  MMR   
10  - 14 years 13Tdap***  Every 10 years 
  Yellow fever  Every 10 years 
  14HPV quadrivalent (males and fe-
males) 
Three doses at 0, 2 and 6 months interval 
> 15 years 5 dose 15TT schedule+ (females 
only) 
See below for the schedule 
Table 2: Vaccines for special groups 
Age Vaccines Notes 
12-15 months 12Men ACYW135 (conjugated) For children in the meningitis belt only. Polysaccha-
ride vaccine is given after 2 years. 
> 1 year Cholera vaccine*+ (Sanchol and 
mORCVAX) 
During epidemics and at refugee camps. 2 doses 14 
days apart and a booster 2 years later 
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• TT 4 - 1 year after 3rd dose: offers protection for 10 
years 
• TT 5 - 1 year after 4th dose: protects throughout 




The manufacturer's instructions should be followed 
strictly. 
When multiple injectable vaccines are required during 
the same visit, they should be given at different sites.  
OPV should be given to children less than five years of 
age at the time of each supplementary immunization 
activity.  
When a dose in the primary series is delayed, resum 
without repeating the previous dose. 
 
Table 3: Typical recommended routine Immunization 
Card  
 
Notes to the schedule 
 
1BCG – Bacillus Calmette-Guerin. It is given intrader-
mally on the upper left arm. 
For children of six months of age and less, mantoux est 
should first be carried out to exclude active infection or 
previous immunity before BCG is given (children less 
than six months do not mount sufficient reaction to tu-
berculin test)15. 
 
2OPV – Oral polio vaccine; two drops given orally. 
Minimum interval between doses is four weeks. 
 
3Hep B - Hepatitis B vaccine is given intramuscularly at 
the outer thigh at birth or soon after-not later than two 
weeks of age. Four doses of Hepatitis B vaccine could 
be given (including the birth dose), but the last dose (3rd 
or 4th) must not be given earlier than 24 weeks (six 
months) and 16 weeks (4 months) from the fist dose.16 
 
4Penta-1 (Hib+DTP+Hep B) – Pentavalent vaccine con-
tains Haemophilus influenza, Diphtheria, Tetanus, Per-
tussis, and Hepatitis B vaccines. It is given intramuscu-
larly on the outer thigh. The third dose is schedul at 
six months due to the Hep B component as explained above. 
Age Vaccines 
 
Birth BCG, OPV 0, Hep B- Birth dose 
6 weeks OPV-1, Penta-1, Rota 1,  PCV-1 
10 weeks OPV-2, Rota 2 
14 weeks OPV-3, Penta-2, PCV-2 
6 months Penta-3, PCV 3, Vit A-1 
9 months Measles-1, Yellow fever 
12-15 months OPV, DTaP, Vit A-2 
18 months Hepatitis A, MMRV 
2 years Typhoid 
5 years OPV, DTaP, MMR 
10  - 14 years Tdap, Yellow fever, HPV (males 
and females) 
> 15 years 5 dose TT schedule (females only) 
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5Rota – Rotavirus vaccine given orally with minimum 
of four weeks interval between doses. Rotarix requires 
two  doses only while RotaTeq requires three doses. The 
first dose of either vaccine is to be given at age not later 
than 15 weeks, and last dose not later than 32 weeks of 
age. Catch-up immunization not recommended. The use 
of rotavirus vaccines should be part of a comprehensiv  
strategy to control diarrhoeal diseases which should in-
clude, among other interventions, improvements in hy-
giene and sanitation, zinc supplementation, community-
based administration of oral rehydration solution and 
overall improvements in case management.12 
 
6PCV13 – 13-valent Pneumococcal conjugate vaccine. 
Second dose should be given at a minimum of 4 weeks 
after 1st dose. Third dose is given at a minimum of two 
months after 2nd dose. 
 
7Vit A  – Vitamin A. Although this is not a vaccine but a 
micronutrient, it is integrated into routine immunization 
as an effective means of raising supplementation cover-
age. It is administered orally at six monthly intervals 
until five years of age. First dose is given at agenot less 
than six months. Dose is 100,000 IU for 6-11 months 
and 200,000 IU for 12 months or less .. 
 
8DTaP – Diptheria, Tetanus and acellular Pertussis vac-
cine. 
9Var   - Varicella vaccine can be given singly or in com-
bination. 
10 MMRV  - Measles, Mumps, Rubella and Varicella 
vaccine. 
11 MMR  – Measles, Mumps and Rubella vaccine. 
12Men A & C  – Meningococcal ACYW135 conjugate 
vaccine. The polysaccharide vaccine is not given to chil-
dren less than 2 years. 
13Tdap – Infant dose of Tetanus and smaller doses of 
Diphtheria and acellular Pertussis vaccine is used for 
boosters to avoid unwanted reactions. 
14HPV – Human papiloma virus vaccine is for both 
males and females. There are 2 types; quadrivalent nd 
bivalent. 
15TT  – Tetanus toxoid. 
 
Catch-up immunization schedule for children < 5 
years who are not previously immunized. 
 
• BCG - for children of six months or less, mantoux 
test should first be carried out to exclude active in-
fection or previous immunity before BCG is given 
(children less than 6 months do not mount sufficient 
reaction to tuberculin test)15. 
• Rotavirus vaccine – last dose must be given not 
later than 32 weeks. Do not initiate rotavirus vacci-
nation if child is 15 weeks or older. 
• Pertussis vaccine – give acellular vaccine in place 
of whole cell if child is above three years. 
• Beside above exceptions, children less than five 
years who are not previously immunized should 
follow the normal recommended schedule maintain-
ing the minimum intervals between doses. 
Vaccine Notes 
BCG Mantoux test should first be carried out to exclude active infection be-
fore BCG is given. 
Tdap Given once, then every 10 years unless a booster is required 
Yellow fever Repeat every 10 years 
5-dose TT All females > 15 years 
HPV quadrivalent (males and females > 
10 years) 
Three doses at 0, 2 and 6 months after dose 0. Not rec mmended after 
26 years 
Typhoid (Vi Polysaccharide) vaccine Re-vaccinate evry 3-7 years 
Varicella 1 dose for < 7 years and 2 doses for > 7 years with 2 months interval 
Catch-up immunization schedule for children 5-18 years who are not previously immunized 
Booster doses of other vaccines should be administered as applicable. 
Additional recommendations  
• Disease surveillance should be institutionalized as 
part of routine services in the health sector. 
• Periodic immunogenicity studies should accompany 
disease surveillance and Routine Immunization as 
part of monitoring and evaluation of vaccine im-
pact.  
• Routine Immunization coverage to be raised ur-
gently to 85-90% for all vaccines. 
• Eradicate vaccine stock-outs by establishing a ro-
bust vaccine forecasting and a special express fund 
release mechanism specifically for vaccines. 
• Maximal exploitation of solar energy for optimum 
vaccine cold chain maintenance. 
• Protect Routine Immunization by ensuring that sup-
plemental immunization activities are not done at 
the expense of Routine Immunization and by allo-
cating more funds for Routine Immunization than 
for SIAs. 
• Development partners must be guided to put the 
global agenda in the context of peculiar country 
situations while Nigeria insists on owning her pro-
grammes and policies. 
• Establish a Nigerian Vaccines and Immunization 
Advisory Committee comprising Paediatricians who 
are immunization experts as chair and majority of 
membership; then Epidemiologists, Immunologists, 
ex-officio members from federal agencies involved  
in vaccine issues as well as non-voting representatives 
from relevant medical and health professional associa-
tions. 
• Institutionalize routine monitoring and reporting of 
adverse events following immunization and inte-
grate it into the pharmaco-vigilance system. 
• Review routine immunization schedule periodically 
to adapt to changing disease and vaccine trends. 
• Integration of routine immunization with other high 
impact child survival interventions such as nutrients 
supplementation. 
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